IN2014DN09718A - - Google Patents
Info
- Publication number
- IN2014DN09718A IN2014DN09718A IN9718DEN2014A IN2014DN09718A IN 2014DN09718 A IN2014DN09718 A IN 2014DN09718A IN 9718DEN2014 A IN9718DEN2014 A IN 9718DEN2014A IN 2014DN09718 A IN2014DN09718 A IN 2014DN09718A
- Authority
- IN
- India
- Prior art keywords
- granulate
- granules
- fatty acid
- binding component
- lactose particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167006 | 2012-05-07 | ||
| PCT/NL2013/050341 WO2013169101A1 (en) | 2012-05-07 | 2013-05-03 | Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09718A true IN2014DN09718A (https=) | 2015-07-31 |
Family
ID=48468727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9718DEN2014 IN2014DN09718A (https=) | 2012-05-07 | 2014-11-18 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150132400A1 (https=) |
| EP (1) | EP2846768B1 (https=) |
| JP (1) | JP2015521175A (https=) |
| CN (1) | CN104363890B (https=) |
| AU (1) | AU2013260246B2 (https=) |
| CA (1) | CA2872689C (https=) |
| ES (1) | ES2600465T3 (https=) |
| IN (1) | IN2014DN09718A (https=) |
| WO (1) | WO2013169101A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53866B1 (sr) | 2008-07-16 | 2015-08-31 | Richter Gedeon Nyrt. | Farmaceutske formulacije koje sadrže ligande dopaminskih receptora |
| EP3160445B1 (en) | 2014-06-26 | 2021-10-20 | Island Breeze Systems Ca, LLC | Mdi related products and methods of use |
| BR122021018502B1 (pt) | 2014-10-21 | 2022-05-03 | United Cannabis Corp | Formulação de canabinoide líquida |
| WO2016205923A1 (en) * | 2015-06-25 | 2016-12-29 | Compressed Perforated Puck Technologies Inc. | Ingestible plant source pill and method |
| BR102015024165A2 (pt) * | 2015-09-18 | 2017-03-28 | Prati Donaduzzi & Cia Ltda | composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso |
| CA2914611A1 (en) * | 2015-12-09 | 2017-06-09 | Mark Kwiecinski | Compositions for improving safety of pharmaceutical formulations |
| AU2017216928B2 (en) * | 2016-02-11 | 2018-09-20 | Gelpell Ag | Oral solid cannabinoid formulations, methods for producing and using thereof |
| US10542770B2 (en) * | 2016-03-18 | 2020-01-28 | Aceso Wellness LLC | Cannabinoid emulsion product and process for making the same |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| WO2019175290A1 (en) | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis or cannabis derived compositions for promoting cessation of chemical dependence |
| WO2019211772A1 (en) * | 2018-05-03 | 2019-11-07 | Radient Technologies Inc. | Obtaining extracts in a solid form |
| CA3106476A1 (en) * | 2018-07-10 | 2020-01-16 | Cardinal Advisory Limited | Formulation of cannabinoid compounds |
| WO2020016656A2 (en) * | 2018-07-18 | 2020-01-23 | Glatt Gmbh | Extended release formulations of cannabinoids |
| US11254633B2 (en) | 2018-10-05 | 2022-02-22 | Jonas Alcirdas Navickas | Cannabis thin layer decarboxylation |
| WO2020183436A1 (en) * | 2019-03-13 | 2020-09-17 | One World Cannabis Ltd. | Dosage forms for oral delivery of cannabinoids, method of preparation and uses of same |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| CA3040547C (en) | 2019-04-17 | 2021-12-07 | Medcan Pharma A/S | Cannabinoid lozenge formulation |
| DE102019211195A1 (de) * | 2019-07-26 | 2021-01-28 | Add Advanced Drug Delivery Technologies Ltd. | Verfahren und Vorrichtung zur Herstellung eines im Wesentlichen im wässrigen Milieu lösbaren Cannabinoid-Granulats |
| EP3946262B1 (en) * | 2019-08-30 | 2024-07-31 | Evie Sa | Loaded granules, their process of production and their uses |
| CN111202767A (zh) * | 2019-09-04 | 2020-05-29 | 汉义生物科技（北京）有限公司 | 大麻全草提取物在改善tau蛋白和β-淀粉样蛋白病理损伤中应用 |
| AU2021308671A1 (en) | 2020-07-17 | 2023-03-02 | Canna-Chemistries Llc | Solid Δ9-tetrahydrocannabinol ( Δ9-THC) compositions |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| IT202000027408A1 (it) * | 2020-11-16 | 2022-05-16 | Indena Spa | Dispersioni solide di cannabidiolo |
| JP2023010676A (ja) * | 2021-07-09 | 2023-01-20 | 株式会社東洋新薬 | 固形組成物 |
| IL317376A (en) | 2022-06-06 | 2025-02-01 | Cannbiorex Pharma Ltd | Formulations and compositions for oral administration containing fat-soluble active ingredients |
| JP7469550B1 (ja) | 2022-10-21 | 2024-04-16 | 第一工業製薬株式会社 | 固体組成物及びその製造方法 |
| JP7360526B1 (ja) | 2022-10-21 | 2023-10-12 | 第一工業製薬株式会社 | 組成物 |
| WO2025032115A1 (en) * | 2023-08-08 | 2025-02-13 | Avextra Portugal Sa | Cannabinoid granule composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1361864T3 (en) | 2001-02-14 | 2014-03-03 | Gw Pharma Ltd | FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids |
| EP1641437A4 (en) * | 2003-07-09 | 2009-06-03 | Chong Kun Dang Pharm Corp | SOLID DISPERSION OF TACROLIMUS |
| DE10341264A1 (de) * | 2003-09-04 | 2005-03-24 | Grünenthal GmbH | Schmelzformulierte, multipartikuläre orale Darreichungsform |
| WO2008033024A2 (en) | 2006-09-15 | 2008-03-20 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
| PL2061427T3 (pl) * | 2006-09-15 | 2011-12-30 | Echo Pharmaceuticals Bv | Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania |
-
2013
- 2013-05-03 ES ES13724009.9T patent/ES2600465T3/es active Active
- 2013-05-03 AU AU2013260246A patent/AU2013260246B2/en active Active
- 2013-05-03 CN CN201380030415.7A patent/CN104363890B/zh active Active
- 2013-05-03 WO PCT/NL2013/050341 patent/WO2013169101A1/en not_active Ceased
- 2013-05-03 EP EP13724009.9A patent/EP2846768B1/en active Active
- 2013-05-03 CA CA2872689A patent/CA2872689C/en active Active
- 2013-05-03 US US14/399,487 patent/US20150132400A1/en not_active Abandoned
- 2013-05-03 JP JP2015511392A patent/JP2015521175A/ja active Pending
-
2014
- 2014-11-18 IN IN9718DEN2014 patent/IN2014DN09718A/en unknown
-
2016
- 2016-07-29 US US15/223,783 patent/US9555019B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104363890A (zh) | 2015-02-18 |
| US20160367522A1 (en) | 2016-12-22 |
| CA2872689A1 (en) | 2013-11-14 |
| EP2846768A1 (en) | 2015-03-18 |
| AU2013260246A1 (en) | 2014-11-27 |
| AU2013260246B2 (en) | 2018-01-25 |
| US20150132400A1 (en) | 2015-05-14 |
| US9555019B2 (en) | 2017-01-31 |
| JP2015521175A (ja) | 2015-07-27 |
| EP2846768B1 (en) | 2016-08-10 |
| CA2872689C (en) | 2021-03-30 |
| WO2013169101A1 (en) | 2013-11-14 |
| ES2600465T3 (es) | 2017-02-09 |
| CN104363890B (zh) | 2018-01-26 |
| AU2013260246A2 (en) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09718A (https=) | ||
| MX2024000327A (es) | Composiciones y metodos para la administracion de arn mensajero. | |
| IL265430A (en) | Pharmaceutical preparations containing a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof | |
| FR2968984B1 (fr) | Composition cosmetiquecomprenant des particules d'aerogel de silice | |
| PH12016500216B1 (en) | Stable pharmaceutical composition and methods of using same | |
| MX347753B (es) | Formulaciones resistentes al abuso. | |
| MY160608A (en) | APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS | |
| MY165048A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| IN2015KN00262A (https=) | ||
| MX2012001939A (es) | Composicion farmaceutica y administraciones de la misma. | |
| MY159630A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
| GEP20156339B (en) | New co-crystals of agomelatine, process for their preparation and pharmaceutical compositions containing them | |
| MX2014012164A (es) | Composiciones a base de probioticos y un complejo de polen de abejas/arcilla, su preparacion y sus usos en nutricion y en terapeutica. | |
| WO2013134534A3 (en) | Solid state forms of cabazitaxel and processes for preparation thereof | |
| MX359554B (es) | Microesferas cristalinas y proceso para fabricacion de las mismas. | |
| WO2014068586A3 (en) | Solid oral compositions of tolvaptan | |
| NZ708199A (en) | Solid dosage form comprising micronized cytisine | |
| WO2014001297A3 (en) | Preparation of composition comprising gas microbubbles | |
| WO2015024577A3 (fr) | Composition a base de safranal | |
| GEP20186881B (en) | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| WO2012114352A3 (en) | Pharmaceutical compositions of maraviroc and process for the preparation thereof | |
| MY153904A (en) | Method of producing pharmacologically pure crystals | |
| WO2013058527A3 (ko) | 류코트리엔 길항제와 에피나스틴의 복합제제 | |
| WO2011098511A3 (fr) | Alumine alpha, utilisation, procédé de synthèse et dispositif associés. | |
| WO2011139255A3 (en) | Pharmaceutical compositions comprising cefetamet |